Stocks · News reference
Johnson & Johnson (NYSE:JNJ) today announced that 24 abstracts featuring clinical data and real-world evidence across the neuropsychiatry portfolio will be presented at the 2026 Psych Congress Annual Meeting
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Johnson & Johnson stock declined 2.22% on September 8, 2026, underperforming the S&P 500's 0.58% loss. The company is expected to report earnings on October 13, 2026, with forecasted EPS of $2.95 (up 5.36% YoY) and revenue of $25.36 billion (up 5.71% YoY). JNJ holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 23.75, trading at a premium to its industry average.
The article compares two healthcare-focused ETFs from iShares: IHE (Pharmaceuticals ETF) with 55 holdings and IYH (Healthcare ETF) with 100 holdings. While IHE delivered stronger 1-year returns of 50% versus IYH's 27.4%, the article recommends IYH as the better choice due to superior 3- and 5-year performance, greater diversification, and larger asset base of $3.9B. Both funds have identical 0.37% expense ratios.
JPMorgan sees healthcare ETF flows reversing, with Eli Lilly and AbbVie among stocks that could benefit from renewed sector rotation.